All News

Chemotherapy is an integral part of treatment for patients with nasopharyngeal carcinoma. Chemotherapy can achieve long-term survival rates of up to 15% to 20%, even in patients with recurrent or metastatic disease. In

Chemotherapy is an integral part of treatment for patients with nasopharyngeal carcinoma. Chemotherapy can achieve long-term survival rates of up to 15% to 20%, even in patients with recurrent or metastatic disease. In

Chemotherapy is an integral part of treatment for patients with nasopharyngeal carcinoma. Chemotherapy can achieve long-term survival rates of up to 15% to 20%, even in patients with recurrent or metastatic disease. In

Three-dimensional (3D) treatment planning refers to the use of software and hardware tools to design and implement more accurate and conformal radiation therapy. This is a major advance in oncology that should lead

Nucleoside analogs have marked efficacy in indolent lymphoid malignancies, but the tradeoff is the challenge of preventing and treating infections in these patients, according to Susan O’Brien, MD, of M. D. Anderson Cancer Center, Houston. At

Laparoscopic surgery for colorectal malignancy is an important topic because of its potential advantages and its oncologic controversies. Drs. Wexner and Hwang have prepared a comprehensive review of the current status of laparoscopic colorectal surgery for malignancy. The relative merits of the new procedure are discussed from a number of perspectives, including the technical aspects of laparoscopic bowel resection, oncologic concerns, and experimental and theoretical effects on tumor growth and host immunity.

Three-dimensional (3D) treatment planning refers to the use of software and hardware tools to design and implement more accurate and conformal radiation therapy. This is a major advance in oncology that should lead

Over the past decade, extensive research and promotion efforts have led to increased awareness and utilization of cancer prevention and screening methods. Many minority groups, however, have not benefited equally from these advances, and continue to have elevated cancer incidence or mortality rates compared with whites.

The increase in serious gram-positive infections has increased the need for treatment of gram-positive infections in patients with hematologic malignancies. Common gram-positive pathogens exhibit a variety of resistance

Bloodstream infections cause significant morbidity and mortality for patients with hematologic malignancy. Antimicrobial drugs are the most reliable currently available treatment for infection, but several issues must be

Neutropenic patients with cancer are a heterogeneous group of patients who carry a variable risk for infection. When such patients present with fever, appropriate empiric antibiotic therapy is initiated and continued until

Risk prediction in patients with neutropenia and fever in a reliable and timely manner has only become possible in the last decade. Patients have been categorized as high risk or low risk based on certain presenting

Three-dimensional (3D) treatment planning refers to the use of software and hardware tools to design and implement more accurate and conformal radiation therapy. This is a major advance in oncology that should lead to

DURBAN, South Africa-Leading experts on HIV/AIDS gathered at the 13th International AIDS Conference, held for the first time in Africa, the continent most severely affected by the pandemic. Experts estimate that 70% of the 34 million people infected with HIV worldwide live in sub-Saharan Africa.

This phase I/II nonrandomized, open-label study was designed to assess the safety and benefit of sequencing irinotecan (Camptosar, CPT-11) plus paclitaxel (Taxol) immediately after cisplatin (Platinol)/etoposide (VePesid,

In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its ability to inhibit potentially lethal radiation damage repair. We conducted a

WASHINGTON-One way to ensure that the right parties receive imaging study results and actually look at them is to make notification nearly fail-safe. A system in use at the Veterans Administration Medical Center, Asheville, NC, as well as other VAs, does exactly that, David M. Schuster, MD, staff radiologist at the hospital, said at the 100th annual meeting of the American Roentgen Ray Society.

Radioimmunotherapy with iodine I-131 tositumomab (Bexxar) produced tumor shrinkage in 97% of previously untreated patients with advanced-stage, low-grade non-Hodgkin’s lymphoma, according to a recent study at the University of Michigan

BETHESDA, Md-The National Cancer Institute-sponsored Early Detection Research Network has issued 13 grants totaling $18 million to complete its first year of funding. Last fall, NCI awarded $8 million to set up the network’s initial operations-18 biomarker development laboratories. The new grants will finance the establishment of the program’s other three components: clinical and epidemiologic centers, biomarker validation laboratories, and a data management and coordinating center.

WASHINGTON-Few were aware of the American Legacy Foundation until last February when it televised and then temporarily pulled two antitobacco advertisements, one of which showed body bags being stacked outside the headquarters of Philip Morris.

SAN FRANCISCO-Surviving cancer is a joyous thing in itself. A new awards program will spotlight that joy and share the stories of 12 survivors who are “everyday heroes,” in an effort to help others who are struggling with the disease.

BETHESDA, Md-Patients have a new, reliable source for information about drugs. The National Library of Medicine has added the US Pharmacopeia’s Drug Information, Vol. II, “Advice for the Patient,” to its MEDLINEplus website. The publication provides extensive information about more than 9,000 brand name, generic prescription, and over-the-counter medications, written in nontechnical language. The information is available at http://medlineplus.gov.

SAN DIEGO-In the VA Cooperative Study 380, screening colonoscopy found advanced adenomas in approximately 10% of asymptomatic veterans, and approximately 20% to 40% of those patients had no lesions within reach of a sigmoidoscope, depending on the insertion depth of the scope.

ROCKVILLE, Md-Last September, medical oncologist Richard Pazdur, MD, became director of the Division of Oncologic Drug Products at the US Food and Drug Administration. Dr. Pazdur joined the FDA after 12 years on the faculty of the University of Texas M.D. Anderson Cancer Center, where his most recent position was professor of medicine and director of educational programs within the Division of Medicine.

NEW YORK-Surgery plus postoperative radiation and chemotherapy should replace surgery alone as standard therapy for most patients with gastric cancer, according to data from Intergroup Study INT-0116. The results were presented at the ASCO meeting by John Macdonald, MD, of St. Vincent’s Cancer Center, New York.

ASCO-A new multicenter international trial is comparing standard systemic pain management with intrathecal therapy for chronic cancer patients.

The author of this reference, Dr. John J. Mulvihill, has a long-standing reputation for studying the complexities of human genetic disorders. His experiences, many publications, and collaborations have focused on various topics, including definition of the

SAN DIEGO-Effective screening for colorectal cancer requires ongoing testing and follow-up. Robert E. Schoen, MD, MPH, of the University of Pittsburgh, reported that adherence with sigmoidoscopy is outstanding-about 86% of eligible subjects returned for a follow-up exam at 3 years. However, a negative experience with screening flexible sigmoidoscopy can keep patients from repeating the procedure. He discussed the findings at an American Gastroenterological Association research forum held during Digestive Disease Week.

BETHESDA, Md-The number of substances “known” or “reasonably anticipated” to cause human cancer now stands at 218, according to the newly published Report on Carcinogens, 9th edition. The new number represents a total increase of 14 substances over the 8th edition. Sixteen substances were added to the previous list, and, for the first time, two were removed.

In addition to the study reported by Friedland, another study of the use of paclitaxel in urothelial cancer was presented at ASCO. This study employed paclitaxel alone on a weekly schedule and showed it to be active in heavily pretreated, advanced urothelial cancers. It should be tested further in chemotherapy-naive patients, according to Catherine M. Broome, MD, of the Northern Virginia Oncology Group, Fairfax.